LTRN · Lantern Pharma Inc.
Substantial doubt about the company's ability to continue as a going concern.
“the existence of substantial doubt regarding our ability to continue as a going concern in the absence of obtaining substantial additional funding”View the 10-Q filed May 15, 2026
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Capacity | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2025-07-01 | $15,530,000 | — | 2025-12-31 | — | 10-K , filed 2026-03-30 |
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2023-12-31 | $499,997 | 10-K, filed 2025-03-27 |
| 2022-12-31 | $2,482,286 | 10-K, filed 2024-03-18 |
| 2021-12-31 | $939,666 | 10-K, filed 2023-03-20 |